| Literature DB >> 21147650 |
E Szaboova1, Zoltan Tomori, P Szabo, S Gresova, V Donic.
Abstract
Nocturnal cardiac arrhythmias (NCA) were analyzed in patients with sleep apnea/hypopnea syndrome (SAHS) and controls. Occurrence and severity of NCA were compared in 33 SAHS patients and 16 control subjects, matched for cardiovascular risk factors. Continuous overnight polysomnography provided ECG, respiratory and sleep parameters for a comparative analysis. Various types and severity of NCA were detected already in moderate SAHS (apnea/hypopnea index = 26 ±15.6/h), reflecting the respiratory and atherosclerotic changes. Moderately severe arrhythmias, represented with benign and 2 complex types were caused by hypoxemia characterized by AHI, minimal SaO2, and lower values after desaturation. Three-time higher prevalence of complex arrhythmias in SAHS patients was not significantly different by usual statistical comparison, likely due to a low number of controls and a joint occurrence of various types and complex severity of arrhythmias in some patients. Therefore, a complex assessment of different types and varying severity of arrhythmias would require a scale specifically constructed for their evaluation.Entities:
Mesh:
Year: 2010 PMID: 21147650 PMCID: PMC4360303 DOI: 10.1186/2047-783x-15-s2-193
Source DB: PubMed Journal: Eur J Med Res ISSN: 0949-2321 Impact factor: 2.175
Figure 1General mechanisms and cardio-respiratory and neuro-physiological effects of sleep disordered breathing.
Baseline, anthropometric, laboratory, and clinical characteristics of subjects.
| SAH (+) n = 33 | SAHS (-) n = 16 | P | |
|---|---|---|---|
| Age (yr) | 52 ± 8 | 48 ± 11 | NS |
| BMI (kg/m2) | 28.9 ± 4.4 | 29.7 ± 4.4 | NS |
| Waist circumference (cm) | 102 ± 10 | 100 ± 12 | NS |
| Total cholesterol (mmol/l) | 5.5 ± 1.01 | 5.1 ± 0.8 | NS |
| TriAcylGlyc (mmol/l) | 2.6 ± 3.9 | 1.9 ± 0.9 | NS |
| HDL-chol (mmol/l) | 1.2 ± 0.3 | 1.2 ± 0.3 | NS |
| LDL-chol (mmol/l) | 3.7 ± 1.2 | 3.1 ± 0.7 | NS |
| Glycemia (mmol/l) | 5.6 ± 0.8 | 5.6 ± 1.2 | NS |
| Age risk (≥ 45 years) (n/%) | 28/85 | 9/56 | NS |
| Positive family history (n/%) | 7/21 | 2/13 | NS |
| AH (n/%) | 21/64 | 7/44 | NS |
| DM (n/%) | 2/6 | 3/19 | NS |
| HLP (n/%) | 18/55 | 9/56 | NS |
| Obesity (BMI) (n/%) | 9/27 | 6/38 | NS |
| Central obesity (Waist) (n/%) | 14/42 | 7/44 | NS |
| Smoking (n/%) | 19/58 | 10/63 | NS |
| ACE inhibitors (n/%) | 11/33 | 5/31 | NS |
| Beta-blockers (n/%) | 11/33 | 9/56 | NS |
| Ca-channel blockers (n/%) | 10/30 | 4/25 | NS |
BMI - body mass index, RF-AS - risk factors for atherosclerosis, AH - arterial hypertension, DM - diabetes mellitus, HLP - hyperlipoproteinemia, use of antihypertensive drugs in subjects with and without SAHS, matched for risk factors.
Carotid ultrasonographic data and cardiovascular diseases as well as respiratory and sleep parameters in subjects with and without SAHS.
| SAHS (+) | SAHS (-) | P | |
|---|---|---|---|
| IMTmax (mm) | 0.91 ± 0.21 | 0.77 ± 0.18 | |
| IMT > 0.85 mm (n/%) | 18/54.5 | 4/25 | |
| Sten 1 (n/%) | 10/30 | 4/25 | NS |
| Sten 2 (n/%) | 2/6 | 0/0 | NS |
| CAD (n/%) | 8/24 | 5/31 | NS |
| Previous MI (n/%) | 5/15 | 3/19 | NS |
| AHI (n/h) | 26.0 ± 15.6 | 4.1 ± 2.6 | |
| Arousal index (n/h) | 22.2 ± 13.7 | 14.9 ± 13.3 | NS |
| MinSaO2(%) | 76.7 ± 10.5 | 87.0 ± 6.5 | |
| AvgO2 (%) | 90.5 ± 4.8 | 91.8 ± 2.4 | NS |
| DeSaO2 (%) | 85.7 ± 4.9 | 88.4 ± 4.8 | |
| Total sleep time (h) | 5.4 ± 1.98 | 5.7 ± 2.0 | NS |
| SaO2 < 90% (%) | 18.8 ± 19.5 | 14.9 ± 13.7 | NS |
IMT - intimomedia thickness, Sten - stenosis 1 = up to 40%, Sten - stenosis 2 = 40-60%, CAD - coronary artery disease, MI - myocardial infarction, SaO2 - arterial oxygen saturation.
Figure 2Recorded: oxygen saturation (SaO.